A new era of potassium intelligence

Proton Intelligence is developing CKM™, an investigational wearable platform designed to turn potassium visibility into actionable insight for clinicians managing cardio-kidney disease.
Investigational device Not cleared or approved for commercial use.
A person checks their CKM companion app while wearing the on-body sensor
CKM™ · On-body sensor
Clinician viewIn range
4.9mM
Event overlay
Target range 3.5–5.2 mM 7.5 6.0 5.2 3.5 3.0 2.5 Hyperkalemia risk · 6.0 Hypokalemia risk · 3.0 Last lab draw ~1 week ago Next scheduled lab ~2 weeks from now Meal · small transient K⁺ rise Oral diuretic · small transient K⁺ dip GDMT medication · small transient K⁺ rise 0 h 12 h 24 h 36 h 48 h
Continuous K⁺ Episodic lab draw Meal Diuretic GDMT
Illustrative only. Not patient data or a representation of device performance.
The problem

Potassium is a critical safety signal measured only in glimpses.

Potassium is a critical safety signal in heart failure and kidney disease care, where dyskalemia can trigger dangerous cardiac arrhythmias. Yet it is still commonly measured through episodic lab or point-of-care testing, leaving clinicians with limited visibility during periods of clinical change.

Why it matters
Dyskalemia in the U.S.
3.7M+
Americans affected by hyperkalemia.¹
35.5M+
Americans affected by hypokalemia.²
Therapy underutilization
>93%
of heart-failure and CKD patients are not on optimal, guideline-directed therapy.³
33%
of U.S. patients discontinued RAASi therapy after a hyperkalemia event.⁴
Worsened patient outcomes
55%
higher risk of heart-failure hospitalization or dialysis initiation.⁴
40%
increase in 6-month mortality after stopping RAASi following a single hyperkalemia event.⁴
Cost burden
$37K
the cost of a single hyperkalemia-related hospitalization.⁵
$15K
increase in cost per month once dialysis starts.⁶
Our solution

A tiny sensor. A new layer of potassium visibility.

CKM™ uses a minimally invasive sensor placed approximately 5 mm beneath the skin to unlock a new layer of potassium visibility for clinicians caring for patients across the cardiorenal care continuum: from acute heart failure to outpatient therapy management and chronic kidney disease.

Sensor placement · cross-section
SKIN SURFACE EPIDERMIS DERMIS SUBCUTANEOUS INTERSTITIAL FLUID CKM™ ≈ 5 mm K⁺ K⁺ K⁺ K⁺ K⁺ 5.2 mM
Clinical context

Potassium risk in heart failure and kidney disease

Potassium (K+) imbalance can be life-threatening in chronic kidney disease and heart failure, often remaining silent until it contributes to cardiac arrhythmia, cardiac arrest, or death.

Progressive · Renal 01
out of range K⁺
Declining K⁺ regulation

Kidney disease

As kidney function declines, the body's ability to regulate K⁺ deteriorates, dramatically increasing risk of dangerous K⁺ fluctuations and acute care events.

Chronic · Outpatient 02
K⁺ no data blind window
Monitoring blind windows

Outpatient heart failure

Lack of K⁺ visibility contributes to fear-driven underutilisation of life-saving GDMT therapies, though they are critical for heart failure management.

Acute · Inpatient 03
K⁺ in range
Rapid intra-day swings

Inpatient heart failure

Potassium shifts rapidly and unpredictably during essential therapies such as IV loop diuresis and guideline-directed medical therapy (GDMT).

Our edge

Four foundations behind CKM™

Disciplined progress, on the record. Each foundation is a place we have done the work — sensing, in humans, in the clinic, and in our IP.

Category builders

Glucose got continuous monitoring twenty years ago. Potassium is next.

Sensing foundation

In vitro data support the core sensing approach across sensitivity, selectivity, and stability.

Human feasibility

Human testing to confirm performance is ongoing with promising results.

Clinical network

Proton is supported by advisors across nephrology, cardiology, emergency medicine, pharmacotherapy, and health policy.

IP protection

Proton's portfolio spans proprietary chemistry, manufacturing, patents, trademarks, and interface concepts.